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ABSTRACT
Background
Markers of kidney dysfunction such as proteinuria or albuminuria have been reported to be
associated with coronary heart disease, but the consistency and strength of any such
relationship has not been clearly defined. This lack of clarity has led to great uncertainty as to
how proteinuria should be treated in the assessment and management of cardiovascular risk.
We therefore undertook a systematic review of published cohort studies aiming to provide a
reliable estimate of the strength of association between proteinuria and coronary heart disease.
Methods and Findings
A meta-analysis of cohort studies was conducted to obtain a summary estimate of the
association between measures of proteinuria and coronary risk. MEDLINE and EMBASE were
searched for studies reporting an age- or multivariate-adjusted estimate and standard error of
the association between proteinuria and coronary heart disease. Studies were excluded if the
majority of the study population had known glomerular disease or were the recipients of renal
transplants. Two independent researchers extracted the estimates of association between
proteinuria (total urinary protein .300 mg/d), microalbuminuria (urinary albumin 30–300 mg/
d), macroalbuminuria (urinary albumin .300 mg/d), and risk of coronary disease from
individual studies. These estimates were combined using a random-effects model. Sensitivity
analyses were conducted to examine possible sources of heterogeneity in effect size. A total of
26 cohort studies were identified involving 169,949 individuals and 7,117 coronary events (27%
fatal). The presence of proteinuria was associated with an approximate 50% increase in
coronary risk (risk ratio 1.47, 95% confidence interval [CI] 1.23–1.74) after adjustment for known
risk factors. For albuminuria, there was evidence of a dose–response relationship: individuals
with microalbuminuria were at 50% greater risk of coronary heart disease (risk ratio 1.47, 95% CI
1.30–1.66) than those without; in those with macroalbuminuria the risk was more than doubled
(risk ratio 2.17, 1.87–2.52). Sensitivity analysis indicated no important differences in prespecified
subgroups.
Conclusion
These data confirm a strong and continuous association between proteinuria and
subsequent risk of coronary heart disease, and suggest that proteinuria should be incorporated
into the assessment of an individual’s cardiovascular risk.
The Editors’ Summary of this article follows the references.
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Over recent decades, substantial progress has been made in
understanding the role that ‘‘classical risk factors’’—namely
blood pressure, smoking, cholesterol, diabetes, and obesity—
play in the aetiology of coronary heart disease (CHD) [1–6].
Subsequent studies and meta-analyses have identiﬁed other
factors that may provide additional important predictive
information regarding the risk of CHD, including inﬂamma-
tory markers [7], haemostatic factors [8,9], left ventricular
hypertrophy, and markers of kidney dysfunction [10].
Kidney disease is highly prevalent worldwide [11–13],
affecting approximately one in six adults in Western
countries. An association between severe kidney failure and
accelerated cardiovascular disease (CVD) has long been
recognized [14]. Markers of early kidney disease, such as the
presence of albumin or protein in the urine, have been
reported to be associated with increased risk of CHD in the
general population [15]. However, inconsistencies in both the
direction and magnitude of the reported relationship have
led to uncertainty about the practical beneﬁt of measuring
these indices in quantifying an individual’s future coronary
risk. Variations in the deﬁnition, measurement, and assess-
ment of proteinuria have added to the confusion, with some
studies reporting on the relationship between urinary
albumin excretion (micro- or macroalbuminuria) and coro-
nary risk, while others have used total urinary protein
excretion, of which albumin is a component.
Previous reports have suggested a positive association
between proteinuria and CHD risk [10], but the strength,
consistency, and independence of the relationship have not
been deﬁned. Hence, the aim of the current study was to
provide reliable estimates of the strength and nature of the
association between proteinuria (urinary protein excretion of
.300 mg/d), microalbuminuria (30–300 mg/d of urinary
albumin excretion), and macroalbuminuria (.300 mg/d) with
subsequent risk of CHD in the general population and in
predeﬁned subgroups (diabetes, gender, and ethnicity).
Methods
Data Sources and Searches
We performed a systematic review of the available
literature according to the MOOSE guidelines [16] for the
Table 1. Definitions of Albuminuria and Proteinuria
Measurement Method Microalbuminuria Macroalbuminuria Proteinuria
24 hour urine collection 30–300 mg/day .300 mg/d .300 mg/d
Spot urine albumin concentration 3–30 mg/dl .30 mg/dl .30 mg/dl
Spot urine dipstick Specific microalbuminuria dipstick positive N/A þ or greater
Spot urine albumin to creatinine ratio 30–300 mg/g or 3.4 g/mmol .300 mg/g or 34 g/mmol .200 mg/g or 23 g/mmol
doi:10.1371/journal.pmed.0050207.t001
Figure 1. Identification Process for Eligible Studies
doi:10.1371/journal.pmed.0050207.g001
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Proteinuria and Coronary Riskconduct of meta-analyses of observational studies. Relevant
studies published between 1966 and November 2006 were
identiﬁed from CINAHL (http://www.ebscohost.com/cinahl/),
EMBASE (http://www.embase.com/), and MEDLINE (http://
ovidsp.tx.ovid.com/spb/ovidweb.cgi and http://www.ncbi.nlm.
nih.gov/sites/entrez?db¼pubmed) using a combined text word
and MeSH heading search strategy that included all spellings
of proteinuria, albuminuria, microalbuminuria, or macro-
albuminuria combined with coronary heart disease, ischemic
heart disease, myocardial infarction, and angina pectoris, and
limited to cohort studies. References from identiﬁed studies
were manually scanned to identify any other relevant studies.
Study Selection and Data Extraction
Cohort studies were included if they reported quantitative
estimates of the age and sex-adjusted relative risk (RR) for
fatal or nonfatal CHD associated with any level of albu-
minuria or proteinuria (Table 1), together with an estimate of
variance (standard error or 95% conﬁdence intervals [CIs]).
Studies were excluded if the study population chieﬂy
comprised pathological subgroups (including hospital-based
populations or those that the majority of the study
population comprised individuals with a history of myocar-
dial infarction, chronic kidney disease, or renal transplanta-
tion), if they reported the estimate of effect with no means by
which to derive the standard error, or if the estimate was not
adjusted for age. Reports from clinical trials were excluded to
avoid potential modiﬁcation of the nature and magnitude of
the relationship between proteinuria and CHD by the
intervention studied (e.g., blood pressure lowering). Studies
reported in languages other than English were included.
CHD mortality was deﬁned as death attributed to ICD9
(International Classiﬁcation of Diseases and Related Health
Problems, Ninth Revision) codes 410 to 414.9 and ICD10
codes I20.0 to I25.9. The prespeciﬁed deﬁnitions of protein-
uria are shown in Table 1. The literature search and data
extraction were conducted by two of the authors (CV and
TN). Where there was disagreement over the eligibility of a
study, three additional authors reviewed the paper until a
consensus was reached (RH, VP, FB).
Data Synthesis and Analyses
Summary estimates of RR were obtained using a random
effects model. Separate summary estimates were obtained for
the RR associated with microalbuminuria, macroalbuminuria,
any albuminuria (micro or macro), and proteinuria. In
addition, some studies reported sex-speciﬁc risk ratios for
the strength of the association, and these were pooled if a
single overall estimate was not provided.
The percentage of variability across studies attributable to
heterogeneity beyond chance was estimated using the I
2
statistic [17]. The 95% CI of the I
2 statistic was calculated using
Table 2. Characteristics of Studies Reporting on the Association between Proteinuria and Subsequent Risk of Coronary Heart Disease
Author and
Reference
Year Country Study
Size
No. CHD
Events
Follow-Up
(Years)
Age Range
(Years)
Study
Population
a
Endpoint
Irie [26] 2006 Japan 90,363 536 10 40–79 General Fatal
Madison [32] 2006 Japan/USA 6,252 1,158 27 45–68 General Fatal þ nonfatal
Lee [29] 2006 USA 4,372 724 12 45–74 General Fatal þ nonfatal
Corona [45] 2005 Mexico 1,509 41 7 35–64 General Fatal þ nonfatal
Tillin [39] 2005 UK 2,965 121 N/A 40–69 General Fatal
Torffvit [40] 2005 Sweden 462 41 12 35 T1DM Fatal þ nonfatal
Wang [43] 2005 Australia 870 89 9 20–74 General Fatal þ nonfatal
Klausen [28] 2004 Denmark 2,762 109 7–9 30–70 General Fatal þ nonfatal
Soedamah-Muthu [38] 2004 Europe 2,329 151 7 15–60 T1DM Fatal þ nonfatal
Yuyun [44] 2004 UK 22,368 800 6.4 40–79 General, DM Fatal þ nonfatal
Leelawattana [30] 2003 Thailand 224 20 4.2 .20 T2DM Fatal
Hu [25] 2002 USA 1,858 126 4 45–74 DM Fatal þ nonfatal
Muntner [35] 2002 USA 8,768 594 16 30–74 General Fatal
Florkowski [23] 2001 NZ 447 187 10 30–82 T2DM NA
Fuller [24]
c 2001 UK/USA 4,743 478 12 46 T1DM, T2DM Fatal þ nonfatal
Culleton [22] 2000 USA 2,586 455 10.5(?) 69 General, DM Fatal þ nonfatal
Jensen [27] 2000 Denmark 204 18 10 30–60 HT Fatal þ nonfatal
Valmadrid [41] 2000 USA 840 242 12 68 DM Fatal
Borch-Johnsen [21] 1999 Denmark 2,085 79 10 30–60 General Fatal þ nonfatal
Lempiainen [31] 1999 Finland 1,069 151 7 65–74 General Fatal þ nonfatal
Mattock [33] 1998 UK 146 65 7 31–64 T2DM Fatal
Beilin [20] 1996 Australia 666 61 4.5 63 T2DM Fatal
Miettinen [34] 1996 Finland 2,431 312 7 45–64 General, T2DM Fatal þ nonfatal
Shimozato [37] 1996 Japan 2,329 24 15.5 .40 General Fatal þ nonfatal
Sasaki [36] 1995 Japan 1,939 62 9.4 53 T2DM Fatal
Wagener [42] 1994 USA 5,362 473 16 45–74 General Fatal þ nonfatal
aStudy population: DM, population with unspecified diabetes type; General, general population; HT, population with hypertension; T1DM, population with type 1 diabetes; T2DM,
population with type II diabetes.
bLevels of adjustment: BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; CAD, coronary artery disease; Cr, serum creatinine; CVD, cerebrovascular disease; DBP, diastolic
blood pressure; DM, diabetes mellitus; ECG, electrocardiogram abnormality; FSG, fasting serum glucose; HbA1c , glycosylated hemoglobin A1c; HDL, high-density lipoproteins; HT,
hypertension; LDL, low-density lipoproteins; LVH, left ventricular hypertrophy; MA, macroalbuminuria; MI, microalbuminuria; PA, physical activity; PVD, peripheral vascular disease; SBP,
systolic blood pressure; TC, total cholesterol; TG, triglycerides; WHR, waist-to-hip ratio.
cMulticentre study (London, Switzerland, Berlin, Hong Kong, Tokyo, Arizona, Oklahoma, Havana, Zagreb, and Warsaw).
doi:10.1371/journal.pmed.0050207.t002
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possible sources of heterogeneity by comparing summary
results obtained when studies were grouped according to
speciﬁc characteristics. Tests for heterogeneity were per-
formed using meta-regression analysis. Publication bias was
assessed using the Egger test and represented graphically
using funnel plots plotting the natural log of the RR versus its
standard error. The trim and ﬁll analysis for publication bias
was performed using Duval and Tweedie’s methods [19]. A p-
value below 0.05 was considered statistically signiﬁcant in all
analyses. All analyses were performed using STATA (Release
9.2; Stata Corporation, http://www.stata.com/).
Results
Literature Search and Characteristics of Studies
The electronic search yielded a total of 3,653 articles, of
which 297 reports were reviewed in full text (see Figure 1). Of
these, 26 studies were eligible for inclusion [20–45], including
information on 169,949 individuals and 7,117 CHD events
(27% fatal). Study size ranged from 146 to 90,363 participants
and the average duration of participant follow-up was 4–27 y
(Table 2).
In total, 26 studies reported the RR for CHD associated
with a measure of proteinuria, and some reported the
relationship for more than one threshold of proteinuria:
ten studies reported on the association between total
proteinuria and CHD; seven studies reported on the
association between microalbuminuria and CHD; nine
studies reported on the association between macroalbumin-
uria and CHD; and six studies reported on the association
between any level of albuminuria and CHD. Levels of
proteinuria were measured using either urinary dipstick tests
for protein or the measurement of the UPCR (urinary
protein–creatinine ratio) on spot urine specimens. The
former was used in the majority of studies (n ¼ 9). Levels of
albuminuria were estimated by measurement of the UACR
(urinary albumin–creatinine ratio) on spot urine specimens.
Twenty-three studies reported hazard ratios, and three
reported odds ratios. Twenty-ﬁve of the studies provided an
estimate that had been adjusted for major CHD risk factors
including blood pressure, smoking, diabetes, and cholesterol
(Table 2).
Association between Proteinuria and Subsequent Risk
of CHD
A total of 16 estimates from ten studies including 124,997
patients reported on the relationship between total protein-
uria and the risk of subsequent CHD (Figure 2). The mean-
weighted estimate from these studies indicated that individ-
uals with proteinuria have an approximately 50% greater risk
of CHD compared with those without the condition: RR 1.47
(95% CI 1.23–1.74). There was considerable heterogeneity
across these studies (p , 0.006) but no signiﬁcant evidence of
publication bias (p ¼ 0.11).
Potential sources of heterogeneity in the strength of the
association between proteinuria and CHD were examined by
conducting sensitivity analyses (Figure 3). There was no
evidence that the strength of the association differed
according to diabetes status, ethnicity (Asian versus non-
Asian, where most Asian participants were from Japan), fatal
versus nonfatal CHD outcomes, laboratory versus dipstick
Table 2. Extended.
Criteria of Endpoint (ICD) Definition of Proteinuria Level of Adjustment
b
ICD 9 (410–414); ICD 10 (I20–I25) Dipstick proteinuria Age, smoking, alcohol, HT, BMI, DM, TC, HDL, Cr
N/A Dipstick proteinuria Age, smoking, alcohol, HT, BMI, DM, TC, PA
N/A Laboratory albuminuria Age, smoking, BP, DM, LDL, HDL
ICD 9 (410.0–410.9) Laboratory albuminuria Age, sex, smoking, BP, DM, TC, LDL, HDL
ICD 9 (410–414.9); ICD10 (I20.0–25.9) Laboratory albuminuria Age, smoking, SBP, glucose tolerance
N/A Laboratory albuminuria Age, sex, SBP, HT treatment, HbA1c, DM duration
ICD 9 (410–414); ICD 10 (I20–25) Laboratory albuminuria Age, sex, smoking, alcohol, BP, BMI, DM, TC
ICD 10 (I20–25.9) Laboratory albuminuria Age, HT, DM, TC, HDL, Cr
ICD 9 (410–414) Laboratory albuminuria Age, DM duration
ICD 9 (410–414); ICD10 (I20–25) Laboratory albuminuria Age, sex, smoking, SBP, BMI, DM, TC
ICD 10 (21,21.4, 21.9, 20, 20.1, 20.8,
20.9, 46.1, 25.5, 42, 50, 50.1, 50.9)
Dipstick proteinuria Age, HDL
N/A Laboratory albuminuria Age, sex, LDL, HDL
ICD 9 (410–414) Dipstick proteinuria Age, sex, ethnicity, SBP, BMI, DM, TC, PA, history of CAD, education level
N/A NA Age, male, smoking, HT, BMI, glucose, HbA1c, DM treatment, TC, TG, HDL, CAD,
CVD, PVD, peripheral neuropathy
ICD 9 (410–414) Dipstick proteinuria Age, smoking, SBP, DM duration, glucose, TC, TG, ECG, retinopathy
N/A Dipstick proteinuria Age, smoking, SBP, DM, TC, HDL, Cr, pre-CVD
ICD 8 (410–414) Laboratory albuminuria Age, sex, smoking, BP, BMI, LDL/HDL
ICD 9 (410–414) Laboratory albuminuria Age, sex, alcohol, HT, insulin use, glycemic control, PA, history of CVD
ICD 9 (410–414) Laboratory albuminuria Age, sex, smoking, SBP, DBP, BMI, TC, TG, HDL
ICD 9 (410–414) Laboratory albuminuria Age, smoking, SBP, WHR, insulin, TG, HDL, history of CVD, LVH
ICD 9 (410–414) Laboratory albuminuria Age, sex, smoking, DBP, HbA1c, TC, pre-CHD
ICD 9 (410–414) Laboratory albuminuria Age, sex, smoking, SBP, DBP, BMI, HbA1c, FSG, TC, TG, HDL, history of CHD, BUN
N/A Laboratory proteinuria Age, sex, smoking, HT, DM duration, HbA1c, TC, TG, HDL, previous CAD, area
N/A Dipstick proteinuria Age, sex, BP, BMI, urine glucose, TC, ECG abnormalities
N/A Dipstick proteinuria Age, sex, HT, obesity, DM duration, FSG, TC, ECG, retinopathy
ICD 9 (410–419) Dipstick proteinuria Age, smoking, SBP, DM, history CVD, education level
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Proteinuria and Coronary Riskmeasurement of proteinuria, duration of study follow-up, or
study size (all p-values for heterogeneity . 0.1).
Association between Albuminuria and Subsequent Risk
of CHD
In the seven studies (n ¼ 31,591 participants) for which
information was available, individuals with microalbuminuria
had a 50% greater risk of subsequent CHD compared with
individuals without, and there was no evidence of hetero-
geneity among included studies: RR 1.47 (95% CI 1.30–1.66); p
for heterogeneity ¼ 0.48 (Figure 4). Evidence of signiﬁcant
publication bias was identiﬁed using the Egger test (p¼0.01),
and after correction for its presence the estimate of the
association was marginally reduced to 1.42 (95% CI 1.23–
1.64). A total of nine studies (n ¼ 34,834 participants)
compared the risk of CHD among individuals with and
without macroalbuminuria. Individuals in whom macro-
albuminuria was detected had double the risk of CHD
compared with individuals without, with no evidence of
publication bias: RR 2.17, 95% CI 1.87–2.52 (Figure 4). Even
after accounting for the fact that we are comparing different
levels of albuminuria with the same control group by using
the Bonferroni correction, the pooled estimates of micro-
albuminuria and macroalbuminuria remained highly signiﬁ-
cant (both p , 0.0001 after Bonferroni correction).
In those six studies (n¼9,972 participants) that reported on
the association between any level of albuminuria the RR for
CHD among individuals with albuminuria was twice that of
normoalbuminuric individuals with no evidence of publica-
tion bias: RR 2.11, 95% CI 1.63–2.73; p for heterogeneity ¼
0.41 (Figure 4).
To examine whether there was a dose–response association
between albuminuria and CHD the following analysis was
restricted to those six studies (n¼31,445 participants) that had
reported separately on the associationbetween microalbumin-
uria and macroalbuminuria and subsequent CHD (Figure 5).
Among these studies, compared with normoalbuminuric
individuals, those with microalbuminuria had a 50% greater
risk of CHD (RR 1.48, 95% CI 1.30–1.68) and in those with
macroalbuminuria, the risk of CHD was more than doubled
(RR 2.55, 95% CI 2.09–3.11; p for heterogeneity , 0.0001).
Impact of Adjustment for Major Cardiovascular Risk
Factors on the Strength of the Association
A total of 12 studies (n ¼ 138,003 participants) reported
estimates of the strength of the association between either
Figure 2. Summary Risk Ratio (95% Confidence Intervals) for the Association of Proteinuria with the Risk of Coronary Heart Disease in Population-Based
Cohort Studies
The black squares are inversely proportional to the variance of the study and the horizontal lines represent the 95% CIs. Footnotes: Four studies
reported estimates separated according to subgroups including (a) female, (b) male, (c) people without diabetes, (d) people with diabetes, (e) people
with type 1 diabetes, and (f) people with type 2 diabetes. References: Culleton 2000 [22]; Fuller 2001 [24]; Irie 2006 [26]; Leelawattana 2003 [30]; Madison
2006 [32]; Miettinen 1996 [34]; Muntner 2002 [35]; Sasaki 1995 [36]; Shimozato 1996 [37]; Wagener 1994 [42].
doi:10.1371/journal.pmed.0050207.g002
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Proteinuria and Coronary Riskproteinuria or albuminuria that were adjusted ﬁrst, by age
and then by other known cardiovascular risk factors (i.e.,
blood pressure, smoking, lipids and diabetes). The overall
age-adjusted summary estimate was 2.55 (95% CI 2.09–3.11),
which was reduced by approximately 50% to 1.78 (95% CI
1.54–2.06; p for heterogeneity ¼ 0.01, Figure 5).
Discussion
This overview of the epidemiological evidence suggests that
proteinuria is independently associated with increased risk of
subsequent CHD. The results from this meta-analysis of 26
cohort studies, including information on over 7,000 CHD
events among almost 170,000 individuals, suggest that people
with proteinuria have a risk of CHD that is at least 50%
greater than those without. Moreover, there was some
evidence to indicate a dose–response relationship such that
the strength of the association was substantially higher among
individuals with macroalbuminuria compared with those with
microalbuminuria. Furthermore, the relationship was con-
sistent across diverse population subgroups including indi-
viduals with and without diabetes. The included studies were
largely population-based suggesting that these ﬁndings are
broadly generalisable and less likely to have been affected by
interventions (e.g., blood pressure lowering) than data from
clinical trials.
The magnitude of the risk is similar to that associated with
many classical risk factors, and stronger than many more
recently discovered risk factors [7,9] suggesting that the
addition of proteinuria may improve the predictive ability of
commonly used cardiovascular risk prediction formulae. This
is being increasingly recognized, with the most recent
cardiovascular disease prevention guidelines from the Amer-
ican Heart Association [46] suggesting that individuals with
proteinuria should be considered to be at similar risk to
people with established CHD. Our data suggest that protein-
uria is likely to improve the ability to predict coronary risk.
Further studies will be required to assess whether the
performance of commonly used risk prediction tools can be
improved by the inclusion of proteinuria in cardiovascular
risk prediction formulae.
Although these data suggest that albuminuria may be a
stronger predictor of coronary risk than urinary total protein
excretion, this may be an artefact of the data, since the
majority of studies that measured urinary protein used
dipstick tests, which have a lower sensitivity and speciﬁcity
than do laboratory estimates. Unfortunately, as only one of
Figure 3. Examination of Potential Sources of Heterogeneity between Studies of Proteinuria and CHD According to Study or Participant Characteristics
Conventions as in Figure 2.
Footnote: (a) One study reported both risk estimates for individuals with and without diabetes.
doi:10.1371/journal.pmed.0050207.g003
PLoS Medicine | www.plosmedicine.org October 2008 | Volume 5 | Issue 10 | e207 1491
Proteinuria and Coronary Riskthe included studies used laboratory estimates to measure
proteinuria, we had limited statistical power in the sensitivity
analysis to be able to detect any real difference between the
two methods. The included studies did not use a speciﬁc
methodology for the collection of the urine specimens,
adding a further potential source of variability [47].
The relationship between proteinuria and CHD was similar
in individuals with and without diabetes, and in the other
subgroups studied. We were unable to assess whether
proteinuria conferred an increased risk of coronary disease
separately to other manifestations of chronic kidney disease,
although others have recently reported that these risks are
additive [48]. Although the impact of therapies that reduce
proteinuria (e.g., blood pressure–lowering agents) have been
the subject of reasonably large trials in people with diabetes
and proteinuria [49,50], fewer data are available regarding the
effects of these therapies in individuals without diabetes and
with proteinuria. The Heart Outcomes Protection Evaluation
(HOPE [51]) suggested that a somewhat greater magnitude of
cardiovascular protection may be associated with the use of
the angiotensin-converting enzyme ramipril in participants
with albuminuria at baseline (relative risk reduction of 26%
versus 15%), although the statistical signiﬁcance of this
difference was not reported. Data from other trials suggest
that the reduction in urinary protein excretion achieved in
an individual predicts the reduction in the risk of subsequent
cardiovascular events [52,53]. The conﬁrmation of a differ-
ential cardiovascular protective efﬁcacy for blood pressure–
lowering agents according to baseline proteinuria in future
studies would further increase the value of adding protein-
Figure 4. Summary Risk Ratio (95% Confidence Intervals) for the Association of Albuminuria with the Risk of Coronary Heart Disease in Population-
Based Cohort Studies
(A) Studies reporting risk estimate of microalbuminuria compared to normoalbuminuria.
(B) Studies reporting risk estimate of macroalbuminuria compared to normoalbuminuria.
(C) Studies reporting risk estimate of any level of albuminuria compared to normoalbuminuria.
Conventions as in Figure 2. Footnotes: Three studies reported separated estimates according to subgroups including (a) female, (b) male, (c) non-Asian
people, and (d) Asian people. References: Beilin 1996 [20]; Borch-Johnsen 1999 [21]; Corona 2005 [45]; Florkowski 2001 [23]; Hu 2002 [25]; Jensen 2000
[27]; Klausen 2004 [28]; Lee 2006 [29]; Lempiainen 1999 [31]; Mattock 1998 [33]; Soedarnah-Muthu 2004 [38]; Tillin 2005 [39]; Torffvit 2005 [40];
Valmadrid 2000 [41]; Wang 2005 [43]; Yuyun 2004 [44].
doi:10.1371/journal.pmed.0050207.g004
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decisions regarding the use of preventative therapies.
Our systematic review could not assess whether proteinuria
plays a causative role in the development of CHD, as this
would require evidence from randomised controlled trials of
therapies that acted mainly by reducing proteinuria. It has
been suggested that proteinuria may simply be a marker of
early vascular disease, as propounded in the ‘‘Steno hypoth-
esis.’’ This hypothesis contends that the presence of protein-
uria reﬂects widespread early vascular disease and abnormal
endothelial function (including that in the glomerular
vasculature), and as such may be a marker of the severity
and duration of other risk factors (e.g., elevated blood
pressure) rather than playing a pathogenic role per se [54].
An important limitation of the current analyses is its
reliance upon published summary data (rather than individ-
ual participant data), which impairs the examination of the
impact of adjustment for known CHD risk factors. In those
studies that provided both adjusted and unadjusted estimates,
the association between proteinuria and CHD was signiﬁ-
cantly attenuated by about 50% after adjustment. Such a
signiﬁcant attenuation in effect size suggests that residual
confounding is likely to remain and, further, that the
summary result presented here may be an overestimate of
the true magnitude of the association between proteinuria
and CHD. Some evidence of publication bias was also
identiﬁed, although after correcting for it, the associations
remained strong and signiﬁcant. Conversely, the strength of
the relationship may have been underestimated due to the
impact of regression dilution bias [55], in which a single
measurement of a risk factor may underestimate the strength
of its relationship to a disease. The effect of regression
dilution bias is supported by the ﬁndings of the study by
Madison et al. [32], in which proteinuria present on two
separate measurements was associated with a much higher
risk of subsequent coronary heart disease than transient
proteinuria (RR 3.72, 95% CI 2.62–5.27 versus 1.48, 1.19–
1.83). Despite these limitations, the results of this systematic
review represent the most precise and accurate estimate of
the strength of the relationship between proteinuria and
CHD currently available.
The ﬁndings of this study therefore strongly support a role
for the evaluation of proteinuria in the prediction of CHD
risk. They suggest that the use of strategies to reduce
proteinuria, and better targeting of other cardioprotective
therapies, may help to reduce the overall burden of CHD.
Studies to assess the impact of these strategies are warranted.
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Editors’ Summary
Background. Coronary heart disease (CHD) is the leading cause of death
among adults in developed countries. With age, fatty deposits called
atherosclerotic plaques coat the walls of arteries, the vessels that nourish
the organs of the body by carrying blood and oxygen to them. Because
they narrow the arteries, atherosclerotic plaques restrict the blood flow
to the body’s organs. If these plaques form in the arteries that feed the
heart muscle (the coronary arteries), the result is CHD. The symptoms of
CHD include shortness of breath and chest pains (angina). In addition, if a
plaque breaks off the wall of a coronary artery, it can completely block
that artery, which kills part of the heart muscle and causes a potentially
fatal heart attack. Smoking, high blood pressure, high blood levels of
cholesterol (a type of fat), having diabetes, being overweight, and being
physically inactive are established risk factors for CHD. Treatments for
CHD include lifestyle changes (for example, losing weight) and
medications that lower blood pressure and blood cholesterol. The
narrowed arteries can also be widened using a device called a stent or
surgically bypassed.
Why Was This Study Done? In addition to the established risk factors
for CHD, several other factors may also increase a person’s risk of
developing CHD, including kidney disease, which affects one in six adults
to some degree. An early sign of kidney dysfunction is high amounts of a
protein called albumin or of total proteins in the urine (albuminuria and
proteinuria, respectively). Some studies have suggested that proteinuria
is associated with an increased risk of CHD, but the results of these
studies are inconsistent. Consequently, it is unclear whether proteinuria
should be considered when assessing and managing an individual’s CHD
risk. In this study, the researchers undertake a systematic review (a study
in which predefined search criteria are used to identify all the research
on a specific topic) and a meta-analysis (a statistical method for
combining the results of several studies) of published studies that have
investigated the association between proteinuria and CHD.
What Did the Researchers Do and Find? The researchers’ systematic
review identified 26 published studies that provided estimates of the
association between CHD risk and proteinuria and albuminuria by
measuring baseline urinary protein and albumin levels in people who
were then followed for several years to see whether they developed
CHD. Nearly 170,000 individuals participated in these studies, which
recorded more 7,000 fatal and nonfatal heart attacks and other coronary
events. In the meta-analysis, proteinuria (urinary protein of more than
300 mg/d or dipstick 1þ or more) increased CHD risk by 50% after
adjustment for other known CHD risk factors. Furthermore, individuals
with microalbuminuria (a urinary albumin of 30–300 mg/d) were 50%
more likely to develop CHD than those with normal amounts of urinary
albumin; people with macroalbuminuria (urinary albumin of more than
300 mg/d) were more than twice as likely to develop CHD. Finally, the
association between proteinuria and CHD did not differ substantially
between specific subgroups of participants such as people with and
without diabetes.
What Do These Findings Mean? These findings suggest that there is a
strong, possibly dose-dependent association between proteinuria and
the risk of CHD and that this association is independent of other known
CHD risk factors, including diabetes. The finding that people with
proteinuria have a 50% or greater increased risk of developing CHD than
people without proteinuria may be a slight overestimate of the strength
of the association between proteinuria because of publication bias. That
is, studies that failed to show an association may not have been
published. However, because this systematic review and meta-analysis
includes several large population-based studies done in various parts of
the world, these findings are likely to be generalizable. Thus, these
findings support the inclusion of an evaluation of proteinuria in the
assessment of CHD risk and suggest that medications and other
strategies that reduce proteinuria might help to reduce the overall
burden of CHD.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050207.
  The MedlinePlus encyclopedia has pages on coronary heart disease,
atherosclerosis, and chronic kidney failure (in English and Spanish)
  Information is available from the US National Heart Lung and Blood
Institute on coronary heart disease
  The UK National Health Service Direct health encyclopedia also
provides information aboutcoronary heart disease (in several lan-
guages)
  Information for patients and caregivers is provided by the American
Heart Association on all aspects of heart disease.
  The British Heart Foundation also provides information on heart
disease and on keeping the heart healthy
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